Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 5/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 3/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.46 |
| ▸ | PRKCG | P05129 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.46 |
| ▸ | LYN | P07948 | 1/20 | 0.46 |
| ▸ | RET | P07949 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29590667 | 1.00 | CNR1 (0.51) | CNR1EPHX2KDREGFRMAPT | |
| SCHEMBL14783172 | 0.95 | MEN1 (0.47) | CNR1EPHX2KDREGFRMAPT | |
| SCHEMBL29590391 | 0.95 | MEN1 (0.47) | CNR1EPHX2KDREGFRMAPT | |
| SCHEMBL15689339 | 0.92 | RAF1 (0.52) | EPHX2MAPTBRAF | |
| SCHEMBL15688915 | 0.92 | IDH1 (0.47) | EPHX2KDRMAPTMEN1KMT2A | |
| SCHEMBL16786677 | 0.90 | MEN1 (0.45) | CNR1KDREGFRMAPTMEN1 | |
| SCHEMBL14783232 | 0.88 | CNR1 (0.53) | CNR1MAPTMEN1KMT2ARAB9A | |
| SCHEMBL29590867 | 0.88 | RAF1 (0.53) | EPHX2KDM4EBRAF | |
| SCHEMBL14783150 | 0.88 | RAF1 (0.53) | EPHX2KDM4EBRAF | |
| SCHEMBL29590409 | 0.88 | MAPT (0.54) | KDRMAPTMEN1KMT2APDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115403531-A | Chemical entities, compositions, and methods as kinase inhibitors | 润新生物公司 | 2022-11-29 | — | — | CN | disclosed |
| US-20220251049-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2022-08-11 | — | — | US | disclosed |
| CN-108794411-B | Certain chemical entities, compositions, and methods | 润新生物公司 | 2022-06-07 | — | — | CN | disclosed |
| US-20210040048-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2021-02-11 | — | — | US | disclosed |
| US-20210040048-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2021-02-11 | — | — | US | disclosed |
| US-10759766-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759766-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3332785-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-3332785-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2020-05-06 | — | — | EP | disclosed |
| US-20200055828-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2020-02-20 | — | — | US | disclosed |
| US-20170183316-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2017-06-29 | — | — | US | disclosed |
| US-20170183316-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2017-06-29 | — | — | US | disclosed |
| US-9518029-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-9518029-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150158826-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150158826-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-06-11 | — | — | US | disclosed |
| CN-104080455-A | Certain chemical entities, compositions, and methods | NEUPHARMA INC | 2014-10-01 | — | — | CN | disclosed |
| EP-2755657-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013040515-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013040515-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183316-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, KRAS | CNR1 2226/4885EPHX2 811/4885KDR 1337/4885 |
| US-20150158826-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, KRAS | CNR1 2226/4885EPHX2 811/4885KDR 1337/4885 |
| US-20210040048-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, KRAS | CNR1 2032/4885EPHX2 904/4885KDR 1385/4885 |
| US-20200055828-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, KRAS | CNR1 2032/4885EPHX2 904/4885KDR 1385/4885 |
| US-10759766-B2 | Certain chemical entities, compositions, and methods | BRAF, NRAS, KRAS | CNR1 2032/4885EPHX2 904/4885KDR 1385/4885 |
| US-20220251049-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, KRAS | CNR1 2032/4885EPHX2 904/4885KDR 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.